2024
Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Mohammad Aghaei A, Weleff J, Martins B, Ing K, Fontenele R, Barnett B, Anand A, Bassir Nia A. Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder. Current Addiction Reports 2024, 11: 685-712. DOI: 10.1007/s40429-024-00574-y.Peer-Reviewed Original ResearchTreatment of AUDUse disorderTreatment of alcohol use disordersModalities of psychotherapyAlcohol use disorderPsychedelic treatmentPsychotherapeutic interventionsTreat AUDPsychedelic compoundsPsychedelic trialsPsychotherapySmall numbers of participantsPsychedelicsMagnitude of improvementMethodological shortcomingsAUDNumbers of participantsClinical trialsDisordersReviewed trialsShort follow-up periodFollow-up periodTherapy methodsEmpirical evidenceNo significant difference
2022
Pregnenolone effects on provoked alcohol craving, anxiety, HPA axis, and autonomic arousal in individuals with alcohol use disorder
Milivojevic V, Sullivan L, Tiber J, Fogelman N, Simpson C, Hermes G, Sinha R. Pregnenolone effects on provoked alcohol craving, anxiety, HPA axis, and autonomic arousal in individuals with alcohol use disorder. Psychopharmacology 2022, 240: 101-114. PMID: 36445398, PMCID: PMC10630889, DOI: 10.1007/s00213-022-06278-3.Peer-Reviewed Original ResearchConceptsAlcohol use disorderDiastolic blood pressureHeart rateGABAergic transmissionNeuroactive steroidsHPA axisRelapse riskUse disordersAlcohol cravingTreatment of AUDAlcohol cue-induced cravingPilot clinical trialStress-induced anxietyCue-induced cravingAutonomic arousalNeurosteroid systemPreg groupStudy drugDBP responseBlood pressureDay groupClinical trialsPregnenolone levelsWeek 2Cue-provoked cravingViral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone
Gonzales P, Bachireddy C, Grieco A, Ding R, de Leon S, Ulrich A, Lama J, Duerr AC, Altice FL. Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 89: 462-471. PMID: 34897226, PMCID: PMC8881312, DOI: 10.1097/qai.0000000000002889.Peer-Reviewed Original ResearchConceptsMSM/transgender womenAlcohol use disorderOral naltrexoneTransgender womenViral suppressionUse disordersEFV/TDF/FTCTreatment of AUDMaximal viral suppressionSingle treatment regimenPlacebo-controlled trialTDF/FTCAntiretroviral therapy adherenceUse of naltrexoneEvidence-based treatmentsViral suppression levelsMVs levelsSecondary outcomesTherapy adherenceLow adherenceAdherence levelsNaltrexoneAUD treatmentHIVPlacebo
2021
Evaluation and Management of Alcohol use Disorder among Older Adults
Joshi P, Duong KT, Trevisan LA, Wilkins KM. Evaluation and Management of Alcohol use Disorder among Older Adults. Current Geriatrics Reports 2021, 10: 82-90. PMID: 34336549, PMCID: PMC8308079, DOI: 10.1007/s13670-021-00359-5.Peer-Reviewed Original ResearchAlcohol use disorderOlder adultsUse disordersTreatment of AUDPatient screening resultsScreening resultsStandardized screening toolsMost older adultsReviewThe prevalenceSUD treatmentPsychosocial treatmentsAlcohol misuseSubstance misuseBrief interventionScreening toolSubstance useMutual help groupsAdultsCOVID-19 pandemicTreatmentPhysical distancingDisordersLaboratory testsScreeningIncreased isolation
2020
Moderation of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms
Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, Hermes G, Fox HC. Moderation of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms. American Journal Of Psychiatry 2020, 178: 447-458. PMID: 33207935, PMCID: PMC8119326, DOI: 10.1176/appi.ajp.2020.20050609.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-1 Receptor AntagonistsAdultAlcohol AbstinenceAlcoholismAnxietyCentral Nervous System DepressantsCounselingCravingDepressionDouble-Blind MethodEthanolFemaleHumansMaleMiddle AgedPrazosinProof of Concept StudySelf-Help GroupsSleep Wake DisordersSubstance Withdrawal SyndromeTreatment OutcomeConceptsAlcohol withdrawal symptomsHeavy drinking daysAlcohol use disorderDrinks/dayWithdrawal symptomsDrinking daysSecondary outcomesPrazosin efficacyAlcohol cravingSelf-reported drinking daysTreatment of AUDEfficacy of prazosinWithdrawal symptom scoresPoor treatment outcomesGlobal disease burdenCurrent alcohol dependencePrimary outcomeTreat analysisAlcohol use outcomesAlcohol intakeSymptom scoresWeek 12Prognostic indicatorDisease burdenSleep disturbancesRace, Ethnicity, and Clinical Features of Alcohol Use Disorder Among US Military Veterans: Results From the National Health and Resilience in Veterans Study
Carr MM, Potenza MN, Serowik KL, Pietrzak RH. Race, Ethnicity, and Clinical Features of Alcohol Use Disorder Among US Military Veterans: Results From the National Health and Resilience in Veterans Study. American Journal On Addictions 2020, 30: 26-33. PMID: 32573050, PMCID: PMC7752825, DOI: 10.1111/ajad.13067.Peer-Reviewed Original ResearchConceptsLifetime alcohol use disorderAlcohol use disorderClinical featuresHigh disease burdenHispanic veteransUS military veteransRace/ethnicityWhite veteransDisease burdenNational HealthUse disordersBlack veteransVeterans StudyTreatment of AUDAnxiety disordersEthnic minority veteransMilitary veteransRepresentative National HealthQuality of lifeSample of veteransRace/ethnic groupsFunctional outcomePsychiatric comorbidityAnalysis of covarianceEthnic groups
2016
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone
Roos CR, Mann K, Witkiewitz K. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addiction Biology 2016, 22: 1528-1539. PMID: 27480445, PMCID: PMC5290305, DOI: 10.1111/adb.12427.Peer-Reviewed Original ResearchConceptsAlcohol use disorderTreatment of AUDOpioid receptor antagonistRandomized clinical trialsBetter drinking outcomesGlutamatergic systemSubtypes of individualsReceptor antagonistClinical trialsRewarding effectsUse disordersClinical decisionDrinking outcomesReward drinkersDrinkersNaltrexoneExcellent reliabilityDifferential benefitsDistinct patterns
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply